Skip to content

Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer

Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02732392
Acronym
SENTINELLE
Enrollment
177
Registered
2016-04-08
Start date
2013-01-09
Completion date
2023-04-07
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient With Prostate Cancer

Brief summary

The diagnosis of a ganglionic infringement(achievement) at a patient reached (affected) by a prostate cancer is a factor(mailman) of bad forecast. The locoregional ganglionic staging is a very important element in the coverage (care). He allows to determine the local extension of the disease and the type(chap) of therapeutics to implement(operate) after the surgery. The standard cleaning out at present recommended by the European company (society) of urology at the patients at intermediate or high risk of second offense (recurrence) after local treatment(processing), has to concern the obturating pit, the internal and external iliac territories. However this type(chap) of cleaning out does not seem to solve all the problems of locoregional stratification. Indeed, several studies concerning the radio-controlled cleaning out highlighted that 10 in 30% of ganglions.

Interventions

PROCEDURElymphadenectomy radio-isotope method

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject man, whose age is greater than or equal to 18 years * Carrier of cancer intermediate risk non-metastatic prostate or high relapse * Subject with an initial balance sheet expansion, regional and general negative by Scanner, abdominopelvic MRI or bone scan, * Subject has undergone a medical examination in connection with the study, * Topic for which a radical prostatectomy is considered curative purposes, * Supported by Subject surgical teams involved in the study, * Topic affiliated to a social security scheme, * Subject who signed informed consent.

Exclusion criteria

* Subject man, whose age is less than 18 years * Subject who have received hormone therapy or radiation therapy for prostate cancer * Subject who had surgery for prostate adenoma (transurethral resection or open surgery) because of potential difficulties injection of radioactive tracer in the gland, * Subject has a history of pelvic surgery or radiotherapy, * Subject with inguinal hernia repair history of laparoscopic, * Subject refusing blood transfusions, * Subject is not agreeing to participate in this study and did not sign the informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Number of sentinel nodes radiolabeled54 monthsNumber of sentinel nodes radiolabeled radiolabeled in the area of standard cleaning

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026